Does the Effectiveness of Thymoglobulin as Measured by T-Cell Depletion Correlate with the Incidence of Acute Rejection Post Kidney Transplant? by O\u27Brien, Makenzie et al.
Lehigh Valley Health Network
LVHN Scholarly Works
Research Scholars Poster Presentation
Does the Effectiveness of Thymoglobulin as
Measured by T-Cell Depletion Correlate with the




Michael J. Moritz MD
Lehigh Valley Health Network, Michael.Moritz@lvhn.org
Follow this and additional works at: https://scholarlyworks.lvhn.org/research-scholars-posters
This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an
authorized administrator. For more information, please contact LibraryServices@lvhn.org.
Published In/Presented At
O'Brien, M., Stansbury, T., Moritz, M., (2018, 3, August) Does the Effectiveness of Thymoglobulin as Measured by T-Cell Depletion
Correlate with the Incidence of Acute Rejection Post Kidney Transplant? Poster presented at LVHN Research Scholar Program Poster
Session, Lehigh Valley Health Network, Allentown, PA.
Lehigh Valley Health Network, Allentown, Pennsylvania
• Thymoglobulin® is one of two standards for 
immunosuppression induction agents for renal 
transplantation and is antibodies derived from rabbits 
against human T-cell markers including CD2 and CD31.  
• CD2 and CD3 are different pan-T cell markers on cell 
surfaces, quantifiable by flow cytometry3,4.
• T lymphocytes are the primary mediator in recognition of 
foreign antigen so their depletion post transplantation 
reduces acute cellular graft rejection5. 
• Grades of kidney graft rejection are defined using the 
Banff 2017 classification of antibody-mediated rejection 
(AMR) and acute-cell mediated rejection (ACR)9..
• Mean CD2 and CD3 counts before 
Thymoglobulin® were 1258.5 ± 545.7 and 
1162.0 ± 501.9 cells/mm3. 
• The mean CD2 and CD3 counts after 
Thymoglobulin® were 10± 33.6 and 8.0± 22.5 in 
patients with no rejection (N=245) and 16 ±
65.6 and 15 ± 60.9 in patients with any level of 
rejection (N=180).
• No association between rejection grade and 
lymphocyte depletion. 
• The purpose of this study was to evaluate the 
relationship between the effectiveness of 
Thymoglobulin® as measured by T lymphocyte 
depletion in preventing rejection.
• Higher post treatment CD2 and CD3 counts are 
associated with increased risk of graft rejection in the 
first post-transplant year
• CD2/CD3 counts are not associated with severity of 
rejection.
• Future studies should look into if additional 
Thymoglobulin® to lower CD2/CD3 counts in patients 
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METHODS
Figure 1: Break 









in the biopsy. 
• A retrospective review of 425 kidney only transplant 
recipients from March 2012 to October 2017. 
• From a complete transplant database the following data 
was extracted: date of transplant, transplant status, 
severity of rejection, CD2 and CD3 measurements from 
the first week and Ascending grades of rejection 





mean CD2 and 
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than patients 
with any type 
of rejection
Figure 3: 
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Received a total of 
5mg/kg of 
Thymoglobulin® 
over 3 daily doses 
and 1.25g of 
methylprednisolone
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